End-To-End Digital Transformation Presents Banks With a Trillion-Dollar Profit Opportunity, Reveals the Newly Launched Temenos Value Benchmark Program
Temenos (SIX: TEMN), the banking software company today announced the first set of results from the Temenos Value Benchmark, a strategic, survey-based program providing in-depth analysis of how software capabilities impact a bank’s profitability. Key findings show that top-performing banks using Temenos software invest in end-to-end digitization, underpinned by state-of-the-art analytics to achieve industry-leading profitability levels.
As a result, these top performing banks using Temenos software have achieved industry-leading cost-income ratios of 25.2% and returns on equity of 25.0%, 2X better than the industry average. These clients also invest over 53% of their IT budget on growth and innovation versus maintenance, which is 2.5X the industry average. These results show the tangible value to be gained if banks are able to digitally transform their businesses and move from legacy-systems to modern, off-the-shelf packaged software running on the latest cloud-native, cloud-agnostic, API-based technology.
Banks are challenged by tough macro-economic conditions, the rise of new competition and evolving customer demands, combined with crippling legacy architectures. However, they have an immense opportunity to harness the power of digitization to transform their business and achieve dramatic profitability improvements. The average return on equity for participating banks in the Temenos Value Benchmark at 15.6% is significantly higher than current industry-average returns on equity of 8% to 10%. This differential translates into up to a massive additional one trillion USD profit potential for the global banking industry were it to digitally transform, assuming a $140 billion increment in operating profit for every 1% increase in return on equity1.
Max Chuard, Chief Executive Officer, Temenos, said: “There is a trillion dollar profit opportunity for banks which move away from legacy systems to modern packaged software running on the latest cloud-native, cloud-agnostic, API-first technology. The case for digital transformation has never been stronger and the urgency for change has never been greater. The results of the Temenos Value Benchmark Program show that Temenos clients are amongst the top performing banks in the industry and by transforming their end-to-end digital banking platform, they have been able to achieve industry-leading profitability levels while innovating faster and delivering exceptional digital experiences for their customers. For most banks, digital transformation is a once in a life project, for us is our full time job. We are proud to take a bank live on our software every day of the week. We help institutions of all types - from large global banks such as Nordea and Standard Chartered to digital-only banks like Varo Money and Volt Bank - to unlock the business value of the digital banking opportunity and drive best-in-class performance and profitability.”
Kanika Hope, Global Strategic Business Advisory Director, Temenos, said: “As the world’s leading provider of packaged banking software, it is our vision and mission to help our clients achieve tangible business value from their IT investment. We therefore launched the Temenos Value Benchmark, a unique program to provide our banking clients, tangible, data-driven insights and recommendations into their business performance, in the spirit of a true strategic partner. Through our benchmark study, we collected thousands of data points around financial and operational metrics as well as qualitative best practices across the entire banking value chain, to understand how specific solution enablers and best practices drive high performance such as better cost-income ratios and improved returns on equity and assets.”
Five Drivers of high-performing banks:
The Temenos Value Benchmark has revealed that top performing banks who have digitally transformed their business and moved away from legacy-systems are able to differentiate across five key areas:
- Product innovation and growth: They launch products and services faster, which result in higher customer growth. These banks can focus their IT spend on growth and innovation rather than maintenance.
- Customer centricity: They engage digitally with more of their customers, cross-sell more and on-board customers faster. All of these contribute to higher customer satisfaction.
- Operational efficiency: They have higher levels of automation driven by straight through processing both, in the front and the back office allowing support of more customers with fewer staff.
- Effective risk and compliance: They have more efficient and effective compliance functions, leading to better staff productivity and more efficient operations. They also spend less of their IT budget on regulation.
- Advanced analytics: They use analytics widely and effectively with a higher proportion of self-service reports and a greater proportion of business users using analytics. They also have a stronger data foundation in terms of lower data duplication across their systems.
Dan Dickinson, CIO, Equitable (EQ) Bank Canada, said: “A great example of the value I got from the Temenos Value Benchmark and why I would encourage my banking counterparts to participate in this program, is the metric I received on the very first page of the report: IT cost as a revenue percentage. This benchmark metric paid off immediately as it revealed to me the true cost of my IT and how I must continue to optimize and automate as I grow my customer base as Canada’s first digital challenger.”
The Temenos Value Benchmark
The Temenos Value Benchmark is a strategic survey-based program to discuss the business and IT metrics and best practices enabled by a bank’s investment in technology. As part of this exercise, banks receive a customized report free of charge comparing their business performance with Temenos clients including executive-level summary of findings with business and IT insights structured along eight banking business and IT domains, across the banking value chain.
To read the insights of the first wave of results from the Temenos Value Benchmark, please visit here.
– Ends –
Temenos AG (SIX: TEMN), headquartered in Geneva, is the world’s leader in banking software, partnering with banks and other financial institutions to transform their businesses and stay ahead of a changing marketplace. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic front office and core banking, payments, fund management and wealth management software products enabling banks to deliver consistent, frictionless customer journeys and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve industry-leading cost-income ratios of 25.2% and returns on equity of 25.0%, 2X better than the industry average. These clients also invest over 53% of their IT budget on growth and innovation versus maintenance, which is 2.5X the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information please visit www.temenos.com.
1 McKinsey Global Banking Review 2017
Jessica Wolfe & Grace Collins
Temenos Global Public Relations
Tel: +1 610 232 2793 & + 44 20 7423 3969
Email : email@example.com
Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Knopp Biosciences Presents Data Further Characterizing Its Lead Kv7.2 Activator Drug Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society’s 2019 Annual Meeting9.12.2019 20:00:00 EET | Press release
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need, today presented data characterizing KB-3061, the lead molecule in the Company’s Kv7 ion channel platform, at the American Epilepsy Society’s (AES) 2019 Annual Meeting in Baltimore, Maryland. Knopp is advancing the development of KB-3061 as a potential precision medicine treatment for the rare, neonatal disease KCNQ2 epileptic encephalopathy (KCNQ2-EE), a genetically defined disease associated with seizures beginning in the first days of life and profound neurodevelopmental delay. The disease is caused by dominant-negative mutations in the KCNQ2 gene, which produces a potassium channel, Kv7.2, critical to early brain development. Data presented at AES by Knopp scientists and its academic collaborators support the continued development of KB-3061 as a potential treatment for children with KCNQ2-EE. K
Murray Energy Corporation Posts Information to its Website Related to Murray Metallurgical9.12.2019 18:46:00 EET | Press release
Beginning on December 2, 2019, Murray Energy Corporation (the “Company”) engaged in confidential discussions under separate confidentiality agreements with certain members of an ad hoc group of superpriority lenders related Murray Metallurgical Coal Holdings, LLC and its subsidiaries (collectively, “Murray Metallurgical”). The confidentiality agreements require the Company to publicly disclose all material non-public information provided to such lenders on or prior to 8:30am (New York time) on December 9, 2019. The Company has posted certain previously undisclosed material to its website to satisfy its disclosure obligations under the confidentiality agreements. Such information can be viewed at the Investors portion of the Company’s website, located at murrayenergycorp.com/investors. Further inquiries should be directed to firstname.lastname@example.org. Safe Harbor Statement The materials referenced in this release and posted to our website include forward-looking statements. A variety of fact
Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 20199.12.2019 18:00:00 EET | Press release
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented nine hematology poster presentations at the 61st American Society of Hematology (ASH) Annual Meeting that underscore its commitment to advancing treatments for rare bleeding disorders by incorporating real-world data and developing innovative adeno-associated virus (AAV) gene therapies. Understanding Real-World Evidence to Advance Patient-Centric Innovation in Bleeding Disorders Real-world evidence from studies across many of Takeda’s portfolio of treatments for hemophilia demonstrate the cost savings and patient benefits resulting from ongoing personalized treatment. However, in von Willebrand disease, real-world evidence highlights the ongoing unmet clinical need for personalization, as it may enable improved treatment outcomes. Insights presented at ASH include: ADYNOVATE ® [Antihemophilic Factor (Recombinant), PEGylated]: In the poster “Real-World Age-Stratified FVIII Consumption and Bleed Outcom
Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting9.12.2019 18:00:00 EET | Press release
Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced additional analyses of results from the ECHELON-1 and ECHELON-2 frontline phase 3 trials of ADCETRIS® (brentuximab vedotin). These analyses were presented at the 61st Annual Meeting of the American Society of Hematology (ASH) taking place December 7-10, 2019 in Orlando, Fla. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical Hodgkin lymphoma and expressed on the surface of several types of peripheral T-cell lymphomas (PTCL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191209005169/en/ The ECHELON-1 analysis highlighted a four-year update of the phase 3 clinical trial in a poster presentation. ECHELON-1 is evaluating ADCETRIS in combination with AVD (Adriamycin [doxorubicin], vinblastine and dacarbazine) compared to ABVD (Adriamycin [doxorubicin], bleomycin, vinblasti
Altasciences to Conduct Clinical Trial for Opioid Use Disorder Under NIH Funding9.12.2019 17:39:00 EET | Press release
Altasciences has been selected by Indivior PLC to conduct "A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 (C4X_3256) Under Fasting and Fed Conditions in Healthy Volunteers", pursuant to the National Institutes of Health (NIH) Funding Opportunity Announcement RFA-DA-19-002, dedicated to the development of medications to prevent and treat opioid use disorder and overdose. The grant was made to Indivior by the NIH in fiscal year 2019, to apply scientific solutions to reverse the national opioid crisis. In March 2018, Indivior entered into a license agreement with C4X Discovery Holdings PLC (C4X) whereby Indivior obtained exclusive global rights to develop and commercialize INDV-2000 (C4X_3256). The first-in-human, single-ascending-dose study will be conducted in two parts — Part I: double-blind, placebo-controlled, randomized, single-ascending-dose study in fasted condition. Part II:
Elliott Statement on Alexion9.12.2019 17:22:00 EET | Press release
Funds advised by Elliott Advisors (UK) Limited (together “Elliott” or “we”) acknowledge the statement issued by Alexion Pharmaceuticals, Inc. (“Alexion” or “the Company”) on Friday. Elliott confirms that it has had a multiyear, constructive and private engagement with Alexion that has led to value-creative changes at the Company. Despite two years of strong execution that bolstered the Company’s strategic value, we believe Alexion remains significantly undervalued by the market. Elliott is encouraged by the Board’s public commitment to evaluate any inbound interest and its overall commitment to shareholder value creation. Elliott remains of the view that Alexion would be a highly valuable strategic and financial asset for a number of larger pharmaceutical companies. We also continue to believe that a proactive approach would maximise the chance of an optimal outcome. We look forward to continuing our dialogue with the Company in an effort to close the gap between its current share pric
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom